SCHEMBL2275857

SCHEMBL2275857

O=C(O)c1ccc(Oc2ccccc2)cc1NC(=O)c1c(Cl)cccc1Cl

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 1/20 0.54
STK39 Q9UEW8 2/20 0.53
PRSS12 P56730 2/20 0.49
HDAC1 Q13547 2/20 0.49
HDAC8 Q9BY41 2/20 0.49
HDAC6 Q9UBN7 2/20 0.49
SLC16A3 O15427 1/20 0.49
PYGL P06737 1/20 0.48
PYGM P11217 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
TLR8 Q9NR97 1/20 0.47
TLR7 Q9NYK1 1/20 0.47
MAPK1 P28482 1/20 0.47
GFER P55789 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2269563 0.88 STK39 (0.57) SERPINE1STK39PRSS12SLC16A3PYGL
SCHEMBL2270366 0.85 STK39 (0.47) SERPINE1STK39HDAC1HDAC8HDAC6
SCHEMBL2274965 0.85 L3MBTL1 (0.49) SERPINE1CYP2C9CYP2C19MEN1KMT2A
SCHEMBL2270119 0.84 PPARG (0.64) SERPINE1STK39PYGLPYGMMEN1
SCHEMBL2270287 0.82 PYGM (0.70) SERPINE1PRSS12HDAC1HDAC8HDAC6
SCHEMBL2273564 0.82 HDAC1 (0.61) SERPINE1PRSS12HDAC1HDAC8HDAC6
SCHEMBL2271588 0.82 SERPINE1 (0.64) SERPINE1PYGLPYGMMEN1KMT2A
SCHEMBL2275201 0.82 ACLY (0.67) SERPINE1STK39PRSS12PYGLPYGM
SCHEMBL2272043 0.82 SERPINE1 (0.75) SERPINE1PRSS12HDAC1HDAC8HDAC6
SCHEMBL2270449 0.81 PYGM (0.56) SERPINE1HDAC1HDAC8HDAC6PYGL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 SERPINE1 101/4885STK39 1878/4885PRSS12 1133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.